Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females

References

• Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–663.
   PubMed Web of Science ®Google Scholar
• Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992;51(1):102–114.
   PubMed Web of Science ®Google Scholar
• Wang JS, Varro A, Lightdale CJ, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol. 2010;105(5):1039–1045.
   PubMed Web of Science ®Google Scholar
• Camilo SM, Almeida EC, Miranzi BA, et al. Endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors. Arq Gastroenterol. 2015;52(1):59–64.
   PubMedGoogle Scholar
• Ligumsky M, Lysy J, Siguencia G, et al. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol. 2001;33(1):32–35.
   PubMed Web of Science ®Google Scholar
• Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest. 2001;31(9):802–811.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Metz DC, Yang YX, et al. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46(2):125–130.
   PubMedGoogle Scholar
• Helgadottir H, Metz DC, Lund SH, et al. Study of gender differences in proton pump inhibitor dose requirements for GERD: a double-blind randomized trial. J Clin Gastroenterol. 2017;51(6):486–493.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol. 1994;37(6):597–604.
   PubMed Web of Science ®Google Scholar
• Ala S, Zanad F, Shiran MR. Population pharmacokinetics of omeprazole in a random Iranian population. Caspian J Intern Med. 2013;4(3):712–716.
   PubMedGoogle Scholar
• Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health. 2005;14(1):19–29.
   Web of Science ®Google Scholar
• Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49(2):158–167.
   PubMed Web of Science ®Google Scholar
• Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37–47.
   PubMed Web of Science ®Google Scholar
• Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13(2):145–153.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Qvigstad G, Fossmark R, et al. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45(4):389–394.
   PubMed Web of Science ®Google Scholar
• Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105(7):1531–1537.
   PubMed Web of Science ®Google Scholar
• Lassen A, Hallas J, Schaffalitzky De Muckadell OB. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther. 2004;20(5):577–583.
   PubMed Web of Science ®Google Scholar
• Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139(4):1115–1127.
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–153.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Rehfeld JF. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia. Scand J Gastroenterol. 2019;54(9):1118–1123.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531–539.
   PubMed Web of Science ®Google Scholar
• Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–1272.
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56(9–10):665–670.
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol. 1985;20(5):569–576.
   PubMed Web of Science ®Google Scholar
• Matsukura N, Onda M, Tokunaga A, et al. Detection of Helicobacter pylori DNA in gastric juice by the polymerase chain reaction: comparison with findings in bacterial culture and the detection of tissue IgA and serum IgG antibodies against Helicobacter pylori. J Gastroenterol. 1995;30(6):689–695.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1997;7(1):75–83.
   Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920.
   PubMed Web of Science ®Google Scholar
• Shin JS, Lee JY, Cho KH, et al. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. Aliment Pharmacol Ther. 2014;40(5):548–561.
   PubMed Web of Science ®Google Scholar
• Andersson T, Andren K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol. 1990;29(5):557–563.
   PubMed Web of Science ®Google Scholar
• McColl KE, Kennerley P. Proton pump inhibitors – differences emerge in hepatic metabolism. Dig Liver Dis. 2002;34(7):461–467.
   PubMedGoogle Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(6):411–426.
   PubMed Web of Science ®Google Scholar
• Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50(2):222–239.
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55(3):177–184.
   PubMed Web of Science ®Google Scholar
• Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44(2):275–283.
   PubMed Web of Science ®Google Scholar
• Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38(4):978–988.
   PubMed Web of Science ®Google Scholar
• Hagymasi K, Mullner K, Herszenyi L, et al. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12(6):873–888.
   PubMed Web of Science ®Google Scholar
• Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol. 1999;11(11):1277–1282.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.
   PubMed Web of Science ®Google Scholar
• Bonapace ES, Fisher RS, Parkman HP. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci. 2000;45(1):34–39.
   PubMed Web of Science ®Google Scholar
• Pregun I, Herszenyi L, Juhasz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion. 2011;84(1):22–28.
   PubMed Web of Science ®Google Scholar
• Feldman M, Richardson CT, Walsh JH. Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest. 1983;71(3):715–720.
   PubMed Web of Science ®Google Scholar
• Prewett EJ, Smith JT, Nwokolo CU, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration profiles in female and male subjects. Clin Sci . 1991;80(6):619–624.
   Web of Science ®Google Scholar
• Archimandritis A, Alegakis G, Theodoropoulos G, et al. Serum gastrin concentrations in healthy males and females of various ages. Acta Hepatogastroenterol . 1979;26(1):58–63.
   PubMedGoogle Scholar
• Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99(3):621–628.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Katsumata R, Gouda K, et al. Hypergastrinemia in long-term use of proton pump inhibitors. Digestion. 2018;97(2):154–162.
   PubMed Web of Science ®Google Scholar
• Card WI, Marks IN. The relationship between the acid output of the stomach following "maximal" histamine stimulation and the parietal cell mass. Clin Sci. 1960;19:147–163.
   PubMed Web of Science ®Google Scholar
• Cox AJ. Stomach size and its relation to chronic peptic ulcer. AMA Arch Pathol. 1952;54(5):407–422.
   PubMedGoogle Scholar
• Leblanc V, Begin C, Corneau L, et al. Gender differences in dietary intakes: what is the contribution of motivational variables? J Hum Nutr Diet. 2015;28(1):37–46.
   PubMed Web of Science ®Google Scholar
• Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol. 2001;21(2):253–259.
   PubMedGoogle Scholar
• Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol. 2003;38(1):36–42.
   PubMed Web of Science ®Google Scholar
• Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007;64(3):386–390.
   PubMed Web of Science ®Google Scholar